Literature DB >> 24389188

Biomarkers and mechanisms associated with recurrent prostate cancer.

Sambad Sharma1, Kounosuke Watabe1.   

Abstract

Prostate cancer is one of the leading causes of cancer death among men in the United States. Although, recent advancement in diagnostic tools has significantly increased early detection and decreased cases of advanced diseases, high numbers of patients who underwent treatment still experience recurrent disease at distant sites, after long periods of remission. Therefore, it is of paramount importance to elucidate the pathological mechanism of the tumor recurrence in order to identify better therapeutic targets and also to distinguish patients with indolent disease from patients with recurrent disease at the time of surgery for optimization of therapeutic intervention. Recurrent tumor cells disseminate at a very early stage even before diagnosis of localized disease and remain dormant as "residual disease" in patients for a long period of time. Colonization and recurrent growth at distant site requires acquisition of genetic and epigenetic alterations and remodeling of signaling pathways. This review focuses on recent advances on identification of biomarkers associated with early and late recurrent disease as well as mechanisms involved during recurrence of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24389188      PMCID: PMC4342748          DOI: 10.2741/4211

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  113 in total

Review 1.  TGF-beta signaling in cancer--a double-edged sword.

Authors:  R J Akhurst; R Derynck
Journal:  Trends Cell Biol       Date:  2001-11       Impact factor: 20.808

Review 2.  Circulating tumor cells as biomarkers in prostate cancer.

Authors:  Daniel C Danila; Martin Fleisher; Howard I Scher
Journal:  Clin Cancer Res       Date:  2011-06-15       Impact factor: 12.531

3.  Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.

Authors:  David R Shaffer; Margaret A Leversha; Daniel C Danila; Oscar Lin; Rita Gonzalez-Espinoza; Bin Gu; Aseem Anand; Katherine Smith; Peter Maslak; Gerald V Doyle; Leon W M M Terstappen; Hans Lilja; Glenn Heller; Martin Fleisher; Howard I Scher
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

4.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

5.  Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.

Authors:  Christine Gjerdrum; Crina Tiron; Torill Høiby; Ingunn Stefansson; Hallvard Haugen; Tone Sandal; Karin Collett; Shan Li; Emmet McCormack; Bjørn Tore Gjertsen; David R Micklem; Lars A Akslen; Carlotta Glackin; James B Lorens
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

6.  The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma.

Authors:  Jonathan A Hickson; Dezheng Huo; Donald J Vander Griend; Anning Lin; Carrie W Rinker-Schaeffer; S Diane Yamada
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

7.  Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model.

Authors:  Haiyen E Zhau; Valerie Odero-Marah; Hui-Wen Lue; Takeo Nomura; Ruoxiang Wang; Gina Chu; Zhi-Ren Liu; Binhua P Zhou; Wen-Chin Huang; Leland W K Chung
Journal:  Clin Exp Metastasis       Date:  2008-06-06       Impact factor: 5.150

Review 8.  Molecular biology of the androgen receptor.

Authors:  Edward P Gelmann
Journal:  J Clin Oncol       Date:  2002-07-01       Impact factor: 44.544

9.  Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone.

Authors:  Aya Kobayashi; Hiroshi Okuda; Fei Xing; Puspa R Pandey; Misako Watabe; Shigeru Hirota; Sudha K Pai; Wen Liu; Koji Fukuda; Christopher Chambers; Andrew Wilber; Kounosuke Watabe
Journal:  J Exp Med       Date:  2011-11-28       Impact factor: 14.307

10.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.